TEVA TO INITIATE THIRD PHASE III TRIAL OF ORAL LAQUINIMOD FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS - Seite 2

inflammation and axonal damage and loss result in the development of progressive
disability.

 ABOUT TEVA
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world´s leading generic drug
maker, with a global product portfolio of more than 1,300 molecules and a direct
presence in about 60 countries. Teva´s branded businesses focus on CNS,
oncology, pain, respiratory and women´s health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $18.3 billion in net revenues in 2011.

ABOUT ACTIVE BIOTECH
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or entering
pivotal phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily
of renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn´s and Lupus. An additional project in clinical development is the orally
administered compound 57-57 for Systemic Sclerosis. Please visit
www.activebiotech.com for more information.

Teva´s Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995: The following discussion and analysis contains forward-
looking statements, which express the current beliefs and expectations of
management. Such statements involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or achievements
to differ significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Important factors that could
cause or contribute to such differences include risks relating to: our ability
to develop and commercialize additional pharmaceutical products, competition
from the introduction of competing generic equivalents and due to increased
governmental pricing pressures, the effects of competition on sales of our
innovative medicines, especially Copaxone® (including competition from
innovative orally-administered alternatives as well as from potential generic
equivalents), potential liability for sales of generic medicines prior to a